UK markets open in 56 minutes

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
29.31-0.95 (-3.14%)
At close: 04:00PM EDT
28.38 -0.93 (-3.17%)
After hours: 06:08PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close30.26
Open30.03
Bid29.26 x 100
Ask29.34 x 200
Day's range29.17 - 30.22
52-week range21.99 - 38.09
Volume337,456
Avg. volume389,598
Market cap1.604B
Beta (5Y monthly)0.99
PE ratio (TTM)1,465.50
EPS (TTM)0.02
Earnings date08 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est40.50
  • GlobeNewswire

    Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

    ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expects to report financial and business results for the first quarter of 2024 after the market closes on Wednesday, May 8, 2024. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to p

  • Benzinga

    Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease

    On Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830, an investigational apomorphine infusion device under FDA review for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD). The FDA has issued a Complete Response Letter (CRL) in response to the company’s New Drug Application (NDA) for SPN-830. The CRL indicates that the review cycle for the application is complete but that the application still needs to be prepa

  • GlobeNewswire

    Supernus Provides Regulatory Update for SPN-830

    ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830. SPN-830 is an investigational apomorphine infusion device for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD) under U.S. Food and Drug Administration (FDA) review. The FD